Remedium Capital Partners, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0002104501

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 6 positions · Total reported value $451.63M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 57.1% · 1 new · 2 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2026 13F filing, Remedium Capital Partners, LLC disclosed 6 equity positions with a combined reported value of $451.63M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were ORKA ($149.00M), SYRE ($129.99M), APGE ($77.87M). By sector, the heaviest allocations are Health Care 82.8%, Other 17.2%.

Versus the prior quarter, Remedium Capital Partners, LLC opened 1 new positions, trimmed 2 and fully exited 1, a turnover rate of 57.1% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest Remedium Capital Partners, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Remedium Capital Partners, LLC, based in West Palm Beach, FL, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 6 positions worth $451.63M in total. HoldingsHub carries 3 quarters of its filings (Q4 2025–Q2 2026).

Firm Snapshot

  • Headquarters: WEST PALM BEACH, FL, United States
  • SEC registration: 801-135411 (status: Approved), registered 2026-05-26
  • Regulatory AUM (Form ADV): $319.00M as of 2026-08-20
  • Website: remediumcp.com

Portfolio Structure

  • 6 positions · $451.63M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: ORKA (ORUKA THERAPEUTICS INC) at 33.0%
  • Average position size: $75.27M

Sector Tilt

  • Health Care 82.8%
  • (classified holdings cover 83% of value)

Quarterly Activity

  • Q2 2026: 2 added
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The Remedium Capital Partners, LLC fund maintained a conservative stance in the 2026-Q2 quarter, reflecting a hold on current positions with slight additions to certain health care stocks. The market view appears to be cautious, possibly reflecting a preference for stability or a wait-and-see approach given the quarter's developments. 2. Key Moves: - Addition: Spire Therapeutics (SYRE) was added with an increase of 0.5% in shares and a 28.78% weight in the portfolio, suggesting a belief in the company's potential growth. - Addition: Apogee Therapeutics (APGE) also saw a small increase of 0.5% in shares and a 17.24% weight, indicating a similar interest in its growth prospects. - No Change: The remaining positions, including ORKA, DMRA, JBIO, and CBIO, were held steady in terms of both shares and weight, indicating a lack of significant change in the market or the company's outlook. - Reduction: No holdings were reduced this quarter. 3. Portfolio Structure: - Passive/Active: The portfolio appears to be more passive, with a hold strategy on most positions rather than active trading. - Sector Bias: The fund has a strong bias towards the health care sector, with five of the top-10 holdings being in this sector. - Risk Appetite: The risk appetite seems moderate, with no significant reductions in holdings and only slight additions. 4. Per-Holding One-Liner: - ORKA: ORKA Therapeutics (ORUKA) is a biotechnology company focusing on the development of treatments for neurological conditions. (unverified) - SYRE: Spire Therapeutics (SPYRE) is a biopharmaceutical company specializing in treatments for central nervous system disorders. (unverified) - APGE: Apogee Therapeutics (APOGEE) is involved in the research and development of treatments for rare genetic disorders. (unverified) - DMRA: Damora Therapeutics (DAMORA) is a biopharmaceutical company developing novel therapies for inflammatory diseases. (unverified) - JBIO: Jade Biosciences (JADE) is a biotechnology company focused on developing targeted therapies for cancer. (unverified) - CBIO: Crescent Pharma (CRESCENT) is a biotechnology company focused on the development of therapies for various diseases, including cancer and neurodegenerative disorders. (unverified) 5. One-Sentence Style Summary: Remedium Capital Partners, LLC maintained a stable health care sector focus with a slight shift towards growth through new additions, reflecting a cautious yet opportunistic approach to investing in the second quarter of 2026.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 82.8%
Other 17.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 1.57M $149.00M 32.99%
32.99%
Hold
2 1.46M $129.99M 28.78%
28.78%
Add
3 586.69K $77.87M 17.24%
17.24%
Add
4 2.05M $53.20M 11.78%
11.78%
Hold
5 1.58M $35.06M 7.76%
7.76%
Hold
6 361.25K $6.50M 1.44%
1.44%
Hold

FAQ

What did Remedium Capital Partners, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Remedium Capital Partners, LLC reported 6 equity positions worth $451.63M in aggregate; its largest disclosed positions were ORKA ($149.00M), SYRE ($129.99M), APGE ($77.87M).

How large is Remedium Capital Partners, LLC's portfolio?

Remedium Capital Partners, LLC reported $451.63M of long equity holdings across 6 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Remedium Capital Partners, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/remedium-capital-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →